Navigation Links
Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/6/2008

entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Orexigen Therapeutics, Inc.

(a development stage company)

Balance Sheets

(In thousands, except share and par value amounts)

September 30, December 31,

2008 2007

(Unaudited)

Assets

Current assets:

Cash and cash equivalents $52,533 $28,967

Investment securities,

available-for-sale 47,561 56,487

Prepaid expenses and other current assets 1,244 2,471

Total current assets 101,338 87,925

Property and equipment, net 2,138 924

Restricted cash 1,125 1,125

Other assets 831 1,346

Total assets $105,432 $91,320

Liabilities and stockholders' equity

Current liabilities:

Accounts payable and accrued expenses $16,919 $8,454

Deferred revenue, current portion 88 88

Long-term debt, current portion 6,404 4,735

Total current liabilities 23,411 13,277

Deferred revenue, less current portion 1,080 1,147

Long-term debt, less current portion 6,095 11,072

Other long-term liabilities 1,430 941

Commitments and contingencies

S
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
2. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
5. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
6. CV Therapeutics Reports 2008 Third Quarter Financial Results
7. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
8. According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists
9. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
10. Nile Therapeutics to Present at Two Upcoming Investor Conferences
11. Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22. 2015  Varian Medical Systems (NYSE: VAR ), ... for its commitment to sustainability with inclusion on a prestigious ... highest ranked healthcare equipment company among the Corporate Knights Global ... Economic Forum at Davos, Switzerland . ...
(Date:1/22/2015)... N.J. , Jan. 22, 2015  Derma Sciences, ... regeneration company focused on advanced wound care, announces ... placental tissues, have been added to the Premier, ... increases the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval ... for the use of Medtronic,s SynchroMed ® II ... for use with United Therapeutics, Remodulin ® (treprostinil) ...
(Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical solutions ... the Company closed its previously announced private placement ... W. Schuler , Birchview Fund LLC and several ... offering expenses.  The proceeds will be used for ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... venture capital in more deals in 2006, but the improvement ... Ernst & Young, LLP and Dow Jones ... in 2006, including a $12 .5 million round by ... for a total of $58.47 million. The total, up from ...
... Lance Armstrong is a unique phenomenon. He's a talented athlete, ... league by himself. Or is he? , ,As many people know, ... National Center for Health Statistics report released by the ... the second year in a row. , ,Cancer patients as political ...
... director of technology programs for the University of Wisconsin-Madison, is ... he demonstrates in Part II of this interview. In ... In Part II (below), he addresses creating a culture of ... also is a featured speaker at the Fusion 2007 ...
Cached Biology Technology:Wisconsin fares slightly better in venture capital chase 2Wisconsin fares slightly better in venture capital chase 3Lance Armstrong and the future of cancer care 2Lance Armstrong and the future of cancer care 3Lance Armstrong and the future of cancer care 4Lance Armstrong and the future of cancer care 5
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a technology ... measures the overall facial feature of a person such ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences International (DSI), ... released a new series of digital telemetry implants ... researchers. M series, part of the PhysioTel™ Digital ... best possible physiologic data when incorporating functional endpoints ...
(Date:12/10/2014)... San Diego has launched an innovative trust network and collaboration ... among social service and care providers by enabling them to ... from the Alliance Healthcare Foundation to expand to organizations serving ... "Live Well San Diego" partner on December 11 th ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... YORK Computed Tomography (CT) scans are an increasingly used ... organ or tissue. The value of CT scanning to diagnose ... these scans being used too frequently, in some cases unnecessarily" ... scans over the course of a persons life" In ...
... parasite has been studied for decades, but surprisingly, little ... cause disease. In a groundbreaking study published November 28 ... research team has for the first time measured which ... during actual infection in humans, not in cell cultures, ...
... new test can identify take-away paper-based food containers (such ... phthalates (plasticisers) are present because the containers were made ... and cardboard. In Italy, where the test was developed, ... packaging breaks food safety rules. Recycling paper and ...
Cached Biology News:Columbia researchers: Growth of CT scan use may lead to significant public health problem 2Columbia researchers: Growth of CT scan use may lead to significant public health problem 3Study of malaria parasite in patient blood finds distinct physiological states 2Study of malaria parasite in patient blood finds distinct physiological states 3Study of malaria parasite in patient blood finds distinct physiological states 4New test finds diisobutyl phthalate in some cardboard food packaging -- recycling is the issue 2
... peptide derived from the C terminal region ... This peptide sequence is downstream from the ... Connexin 36 antibody Cat. No. 51-6300. ... Reactivity: Mouse (positive control: mouse Connexin 36-transfected ...
Invitrogen's Calcium Phosphate Transfection Kit provides high-quality reagents to enable the introduction of DNA into tissue culture cells via calcium phosphate co-precipitation....
...
...
Biology Products: